---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-022122"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:24:40.051296+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PAVmed Q3 net loss $6.3M; Veris relaunches implant monitor; Lucid gets Medicare support

## Summary
- GAAP net loss $6.3M ($0.29 diluted EPS); non-GAAP adj loss $0.4M ($0.02) for Q3 2025.
- Lucid Diagnostics: $1.2M EsoGuard revenue, 2,841 tests processed; CAC unanimously supported Medicare coverage.
- Veris Health launched commercial phase of OSU partnership, relaunched implantable monitor for planned 2026 FDA submission.
- PAVmed signed LOI with Duke University to license endoscopic esophageal imaging technology via new subsidiary.
- PAVmed cash $3.1M (Sep 30) vs $1.2M (Dec 31, 2024); Lucid netted ~$27M from public offering.

## SEC filing metadata
- accession: 0001493152-25-022122
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315225022122/0001493152-25-022122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315225022122/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-022122
- JSON: https://secwatch.observer/filing/0001493152-25-022122.json
- Plain text: https://secwatch.observer/filing/0001493152-25-022122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.